INTRODUCTION
T raditionally, the definition of recurrence risk in patients with papillary thyroid carcinoma (PTC) is based on histological data (size, number of foci and subtype of the tumor; extrathyroid and vascular invasion; metastases) and tumor resection (1) (2) (3) (4) . Some studies suggested the diagnosis of PTC in a relative(s) to be a risk factor for recurrence (5) (6) (7) (8) (9) (10) . Since this information has not been included in risk stratification (1) (2) (3) (4) and one of the main objectives of this stratification is to guide therapy, it is important to know whether the diagnosis of PTC in a first-degree relative would influence (or modify) the current therapeutic recommendations.
With respect to treatment of PTC, there is agreement that total thyroidectomy is the most adequate initial procedure (1) (2) (3) (4) . In the presence of clinically apparent metastases (cN1), therapeutic lymph node dissection is also consensus (1) (2) (3) (4) . Similarly, treatment or adjuvant therapy with 131 I and TSH suppression have been recommended for patients with incomplete tumor resection, persistent disease, or high risk for recurrence (1-4). Obviously, a family history does not modify these managements. Therefore, the controversy regarding the possible importance of family history for therapy lies in subjects who are at low risk of recurrence and for whom elective cervical lymph node dissection, ablation with 131 I or TSH suppression have not been recommended (1) (2) (3) (4) .
The objective of this prospective study was to determine whether the currently recommended therapy for patients with PTC who show no classical factors indicating a poor prognosis (no cervical lymph node dissection, ablation with 131 I or TSH suppression) is also effective when they have a family history of this tumor.
SUBJECTS AND METHODS
First, 723 siblings of 447 patients with PTC (a single case in the family until that time) were screened by ultrasonography (US) (11) . This screening resulted in the diagnosis of PTC in one additional relative in 21 families and in two additional relatives in 11 families (11) . These 43 cases detected by US screening were included in this prospective study. Family syndromes associated with PTC such as familial adenomatous polyposis, Gardner's syndrome, Cowden disease, Werner's syndrome, and Carney's complex were excluded in all patients.
The extent of surgery was defined according to the criteria shown in table 1. Ten patients were submitted to lobectomy, 23 to total thyroidectomy without lymph node dissection, and 10 to total thyroidectomy and lymph node dissection. In patients undergoing lobectomy, measurement of serum thyroglobulin (Tg) and anti-Tg antibodies (TgAb) during therapy with levothyroxine (L-T4) and neck US were performed 6 months after surgery and then annually.
In patients treated with total thyroidectomy, ablation with 131 I was indicated according to the algorithm shown in figure 1. Only one patient received radioiodine due to the presence of 5 metastatic lymph nodes. This patient was excluded from the study. One year after total thyroidectomy, the patients were evaluated according to the algorithm shown in figure 2 . After, the patients were followed up by serum measurement of basal Tg and TgAb and annual US. The time of follow-up ranged from 24 to 72 months (median 50 months). The imaging methods did not detect apparent metastases in any of the patients during follow-up after surgery. The behavior of tumor markers (Tg and TgAb) during follow-up are shown in table 3.
Tg/T4: thyroglobulin measured during levothyroxine therapy; TgAb: anti-thyroglobulin antibodies; rhTSH: recombinant human TSH; US: ultrasonography; CT: computed tomography. US was performed with a linear multifrequency 14 MHz transducer for morphological analysis and for power Doppler evaluation. US was defined as negative when no suspicious lesions were detected (12, 13) or, in the presence of these lesions, when cytology and Tg measurement in the needle washout fluid obtained by USguided fine-needle aspiration were negative. Chest and mediastinal computed tomography (CT) was performed on 5-mm sequential sections. FDG-PET/CT was carried out after stimulation with recombinant human TSH.
RESULTS
Thirty of the 42 patients included were women and 12 were men. Patient age ranged from 14 to 67 years (mean 35 years). TNM stage and risk stratification are shown in table 2. With respect to tumor size > 1 cm, multicentricity, extrathyroid invasion and clinically apparent lymph node metastases (cN1), 30 patients presented at least one finding and 14 had at least two of these findings. 
DISCUSSION
Some studies have shown a higher risk of recurrence in the case of family aggregation of PTC compared to sporadic PTC (5-10), but this observation is not confirmed in all studies (14) (15) (16) (17) (18) (19) (20) . There is even greater controversy to know whether the possible increased risk is due to the more aggressive initial presentation or whether a family history itself is an independent risk factor for recurrence (14) . This information is important to define whether patients with a family history of PTC require more aggressive treatment than the one usually recommended, as proposed by some authors (6, 21, 22) . More aggressive therapy (including 131 I and TSH suppression) is already recommended for patients with incomplete tumor resection, persistent disease immediately after surgery or high risk of recurrence, irrespective of family history (1-4) . Therefore, the controversy is restricted to cases that show no classical factors indicating a poor prognosis, which was the objective of this prospective study. The present results suggest that the common recommendation of total thyroidectomy without elective lymph node dissection, ablation with 131 I or TSH suppression seems to be sufficient in these patients, even in the presence of a family history of PTC (1) (2) (3) (4) . Based on the characteristics of the patients included in the study, this conclusion only applies to those presenting the criteria shown in table 4, which were observed in all of them. the first 5 years of follow-up (23) . In addition, the results found [US persistently showing no anomalies associated with basal Tg ≤ 0.2 ng/mL (24) or stimulated Tg < 1-2 ng/mL (24); stable or declining Tg (25) (26) (27) , or TgAb reduction > 50% (28) ] make the occurrence of long-term recurrence rates that would modify the conclusion of the study unlikely. On the other hand, strengths of the study are its prospective design using pre-defined and uniform initial therapy and follow-up; inclusion of exactly the group of patients for which controversy exists; the therapy performed (no elective lymph node dissection, ablation with 131 I or TSH suppression); and even the surprising result (absence of apparent recurrence). Specifically in this subgroup of patients (PTC ≤ 2 cm and no unfavorable risk factors), there is low risk of structural disease recurrence after less extensive surgery and without radioiodine (29) . In fact, we reviewed the data of 58 patients seen at our institution, who were similar to the present patients (nonaggressive PTC ≤ 2 cm) and were submitted to the same therapy and follow-up, but who had sporadic tumors (30, 31) . None case of recurrence was also detected in this group (30, 31) .
In conclusion, the treatment usually recommended for patients with PTC who show no unfavorable risk factors (1-4) does not need to be modified in the presence of a family history of this tumor. Studies involving a larger number of patients are needed to confirm this conclusion.
Disclosure: no potential conflict of interest relevant to this article was reported. Another doubt is related to the question whether a poor prognosis of PTC exists only when three or more relatives are affected (5, 7) . Studies have shown a more aggressive behavior of the tumor even when there are only two relatives affected (6) (7) (8) (9) (10) . In the present series, no recurrence was observed even in patients of families with three affected relatives.
The present study has some limitations. The first is the small number of patients included, but the lack of recurrence minimizes the relevance of sample size. The second limitation is the time of follow-up; however, it is known that approximately 80% of recurrences occur in
